Request Sample Form


Phone No.*:


Service Intersted In:

Download Complete Report

Your Name*:


Contact Number*:


Service Interested In* (required)

Your Requirment*:

Orphan Drug Designation granted for AZ’ Imfinzi

AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Imfinzi (durvalumab) for the treatment of small cell lung cancer (SCLC).

July 12th, 2019|News|

Roche launches first in vitro lung cancer diagnostic test

Roche Diagnostics has launched its first in vitro diagnostic test to target ROS1 positive lung cancers, VENTANA ROS1 (SP384) Antibody.

June 10th, 2019|News|

Possible drug target for lung cancer by manipulating tumor suppressor protein Rb

Tumours often become resistant to treatment, but how this occurs is poorly understood. An analysis of how the protein Rb affects tumour growth and the response to therapy might cast light on the problem.

May 1st, 2019|News|

Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Toronto, Canada.

September 25th, 2018|News|